Literature DB >> 34027566

LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data.

Tae-Hyung Kim1,2, Sungmin Woo3, Ijin Joo1,4, Mustafa R Bashir5,6,7,8, Mi-Suk Park9, Lauren M B Burke5,8, Mishal Mendiratta-Lala10, Richard K G Do11.   

Abstract

PURPOSE: To perform a systematic review and meta-analysis using individual patient data to investigate the diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) Treatment Response (TR) algorithm for detecting incomplete necrosis on pathology.
METHODS: PubMed and EMBASE were searched from Jan 1, 2017 until October 14, 2020. Studies reporting diagnostic accuracy of LI-RADS TR algorithm on CT or MRI for detecting incomplete necrosis on pathology as a reference standard were included. Sensitivity and specificity were pooled using random-effects model. Subgroup analyses were performed for locoregional treatment (LRT) type and imaging modality.
RESULTS: Six studies (393 patients, 534 lesions) were included. Pooled sensitivity was 0.56 (95% confidence interval [CI] 0.43-0.69) and specificity was 0.91 (95%CI 0.84-0.96). Pooled sensitivity was highest using arterial phase hyperenhancement (APHE) (0.67 [95%CI 0.51-0.81]), followed by washout (0.43 [95%CI 0.26-0.62]) and enhancement similar to pretreatment (0.24 [95%CI 0.15-0.36]). Among lesions with incomplete necrosis, 2% (95%CI 0.00-0.05) manifested as washout but no APHE; 0% (95% CI 0.00-0.02) as enhancement similar to pretreatment without both APHE and washout. Pooled sensitivity was lower after ablation than embolization (0.42 [95%CI, 0.28-0.57] vs. 0.65 [95%CI, 0.53-0.77], p = 0.033). MRI and CT were comparable (p = 0.783 and 0.290 for sensitivity and specificity).
CONCLUSIONS: LI-RADS TR algorithm shows moderate sensitivity and high specificity for detecting incomplete necrosis after LRT. APHE is the dominant criterion, a washout contributes to small but meaningful extent, while the contribution of enhancement similar to pretreatment may be negligible. LRT type may affect performance of the algorithm.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Hepatocellular carcinoma; Individual patient data; Liver imaging reporting and data system (LI-RADS); Meta-analysis; Systematic review; Treatment response

Mesh:

Substances:

Year:  2021        PMID: 34027566      PMCID: PMC9358967          DOI: 10.1007/s00261-021-03122-8

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  34 in total

1.  The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed.

Authors:  Jonathan J Deeks; Petra Macaskill; Les Irwig
Journal:  J Clin Epidemiol       Date:  2005-09       Impact factor: 6.437

2.  Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy.

Authors:  Eric C Ehman; Sarah E Umetsu; Michael A Ohliger; Nicholas Fidelman; Linda D Ferrell; Ben M Yeh; Judy Yee; Thomas A Hope
Journal:  Abdom Radiol (NY)       Date:  2016-11

3.  The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.

Authors:  Mohammad Chaudhry; Katrina A McGinty; Benjamin Mervak; Reginald Lerebours; Cai Li; Erin Shropshire; James Ronald; Leah Commander; Johann Hertel; Sheng Luo; Mustafa R Bashir; Lauren M B Burke
Journal:  Radiology       Date:  2019-12-17       Impact factor: 11.105

4.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

5.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement.

Authors:  Matthew D F McInnes; David Moher; Brett D Thombs; Trevor A McGrath; Patrick M Bossuyt; Tammy Clifford; Jérémie F Cohen; Jonathan J Deeks; Constantine Gatsonis; Lotty Hooft; Harriet A Hunt; Christopher J Hyde; Daniël A Korevaar; Mariska M G Leeflang; Petra Macaskill; Johannes B Reitsma; Rachel Rodin; Anne W S Rutjes; Jean-Paul Salameh; Adrienne Stevens; Yemisi Takwoingi; Marcello Tonelli; Laura Weeks; Penny Whiting; Brian H Willis
Journal:  JAMA       Date:  2018-01-23       Impact factor: 56.272

6.  Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation.

Authors:  Giuseppe Brancatelli; Richard L Baron; Mark S Peterson; Wallis Marsh
Journal:  AJR Am J Roentgenol       Date:  2003-04       Impact factor: 3.959

7.  Evaluation of tumor recurrence after superselective conventional transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging.

Authors:  Shiro Miyayama; Masashi Yamashiro; Keiichi Nagai; Jun Tohyama; Kenshi Kawamura; Miki Yoshida; Naoko Sakuragawa
Journal:  Hepatol Res       Date:  2016-02-24       Impact factor: 4.288

8.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

9.  LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.

Authors:  Erin L Shropshire; Mohammad Chaudhry; Chad M Miller; Brian C Allen; Erol Bozdogan; Diana M Cardona; Lindsay Y King; Gemini L Janas; Richard K Do; Charles Y Kim; James Ronald; Mustafa R Bashir
Journal:  Radiology       Date:  2019-04-30       Impact factor: 29.146

10.  Conducting systematic reviews of diagnostic studies: didactic guidelines.

Authors:  Walter L Devillé; Frank Buntinx; Lex M Bouter; Victor M Montori; Henrica C W de Vet; Danielle A W M van der Windt; P Dick Bezemer
Journal:  BMC Med Res Methodol       Date:  2002-07-03       Impact factor: 4.615

View more
  2 in total

1.  CLEC14A was up-regulated in hepatocellular carcinoma and may function as a potential diagnostic biomarker.

Authors:  Lang Yan; Xiang Li; Yunfeng Yuan
Journal:  Clinics (Sao Paulo)       Date:  2022-05-13       Impact factor: 2.898

2.  LI-RADS Treatment Response versus Modified RECIST for Diagnosing Viable Hepatocellular Carcinoma after Locoregional Therapy: A Systematic Review and Meta-Analysis of Comparative Studies.

Authors:  Dong Hwan Kim; Bohyun Kim; Joon-Il Choi; Soon Nam Oh; Sung Eun Rha
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2022-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.